skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Executive Summary

Using Pharmapremia data, we analyze performance metrics for a select group of leading cancer companies to see where the sticking points are and who is winning at industry’s most important race.

 

Pharmapremia_Oncology_Scorecard

 

As oncology drug development programs skyrocket and companies prioritize the therapeutic area, there’s a need to understand what is working and where the process needs to be improved.

Using performance metrics from Informa Pharma Intelligence’s Pharmapremia on transitions between clinical phases and the likelihood of approval from 2006-2010 and 2011-2015, it’s clear that as the number of cancer development programs has risen, success rates aren’t holding up.

“Despite the fact that more oncology candidates transitioned through and out of company pipelines over the last five years compared to the previous five, overall success rates took a dive industry-wide,” Informa Pharma Consulting’s Justin Burns said. “These data underscore just how dedicated the pharmaceutical industry has been, especially the major companies, to advancing the treatment paradigm for cancer.”

While performance was down strictly looking at success rates, Burns noted that for select companies that have concentrated on cancer, there has been an increase in overall approvals, from 39 to 52 for 2006-2010 and 2011-2015, respectively. “Despite the fact that the harder they tried, the more they failed, these companies continued to devote considerable R&D spend to their cancer pipelines,” he commented.

See below for more on which companies are standing above the pack and which areas have the best odds to make it to market.

 

Oncology Scorecard

 

 

Discover Who is Succeeding at Cancer Drug Development from Pharma Intelligence

 

Read also

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • Biomedtracker: follow the drug development process

    Biomedtracker 2018 Early Outlook Report

    What's on the horizon for pharma in 2018? Find out with Biomedtracker&rsquo;s Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.<br />

    Topics Drug development landscape

  • Scrip: industry news and insights

    Bayer Bets On Oncology Pipeline Vows To Increase 2017 R&D Budget

    By Lucie Ellis 22 Feb 2017

    Bayer has launched an internal oncology R&amp;D unit to speed up development of its pipeline cancer therapies and ensure the company is first to market with its late-stage treatment candidates, head of pharma Dieter Weinand told Scrip on the sidelines of the pharma's annual results conference.

    Topics Cancer

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: